Brief: Newamsterdam Pharma Announces 2024 Strategic Priorities

NewAmsterdam Pharma

04/01/2024 13:58

Jan 4 (Reuters) - 
  
    * NEWAMSTERDAM PHARMA ANNOUNCES 2024 STRATEGIC PRIORITIES
    * POSITIONED FOR THREE PHASE 3 TRIAL READOUTS OVER NEXT 18
MONTHS
    * TOPLINE DATA EXPECTED FROM PHASE 3 BROOKLYN TRIAL IN HEFH
IN 3Q
2024 AND BROADWAY TRIAL IN ASCVD IN 4Q 2024
    * PLAN TO INITIATE TANDEM, PIVOTAL PHASE 3 TRIAL EVALUATING
OBICETRAPIB & EZETIMIBE FIXED-DOSE COMBINATION, IN 1Q 2024
    * ON-TRACK TO COMPLETE ENROLLMENT IN PHASE 3 PREVAIL CVOT IN
1Q
2024
    * PHASE 3 PREVAIL CVOT TOPLINE DATA EXPECTED IN 2026
    * EXISTING CASH WILL BE SUFFICIENT TO FUND COMPANY'S
OPERATIONS
THROUGH 2026

Source text for Eikon:  ID:nGNX9LHRK0 
Further company coverage: [ ]

 ((Reuters.Briefs@thomsonreuters.com;))